Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphisms

5 May 2006

Abstract excerpt

OBJECTIVE: Patients initiating docetaxel chemotherapy were genotyped for CYP3A4, CYP3A5, MDR1, GSTM1, GSTT1, GSTM3, and GSTP1 to identify variability factors of docetaxel pharmacokinetics and toxicity. METHODS: Genotyping was performed by direct sequencing (CYP3A4), real-time polymerase chain reaction (CYP3A5), and polymerase chain reaction-restriction fragment length polymorphism (MDR1 and GST). The clearance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Glutathione Transferases and Polymorphisms
Share to Neutropenia and Cancer Infections

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16765145
DOI: 10.1016/j.clpt.2006.02.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphismsPMID 16765145Read ↗

Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies.Semantic proximity Read ↗

Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel.Semantic proximity Read ↗

Association between gene polymorphism and adverse effects in cancer patients receiving docetaxel treatment: a meta-analysis.Semantic proximity Read ↗

Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy.Semantic proximity Read ↗

The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients.Semantic proximity Read ↗

Dexamethasone as a probe for docetaxel clearance.Semantic proximity Read ↗

Investigating the influence of relevant pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of orally administered docetaxel combined with ritonavir.Semantic proximity Read ↗

Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics.Semantic proximity Read ↗

Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel.Semantic proximity Read ↗

Pharmacogenetic impact of docetaxel on neoadjuvant treatment of breast cancer patients.Semantic proximity Read ↗

Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam.Semantic proximity Read ↗

Pharmacogenetic pathway analysis of docetaxel elimination.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.